Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma-Reference-Cited by-同舟云学术

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma

Published:2020-04-09 Issue:1 Volume:1 Page:122-132
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Torka Pallawi¹^ORCID,Mavis Cory¹,Kothari Shalin²,Belliotti Sarah¹,Gu Juan¹,Sundaram Suchitra¹,Barth Matthew¹,Hernandez‐Ilizaliturri Francisco J.¹

Affiliation:

1. Roswell Park Comprehensive Cancer Center Buffalo New York USA

2. Yale University School of Medicine New Haven Connecticut USA

Funder

National Cancer Institute

Roswell Park Cancer Institute

Ministerstvo Zdravotnictví Ceské Republiky

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.2

Reference32 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

2. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

3. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

4. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways;Biomarker Research;2024-01-08

2. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy;Molecular Therapy;2023-11

3. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia;Leukemia;2023-04-08

4. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma;Blood Cancer Journal;2023-01-11

5. Targeting cullin neddylation for cancer and fibrotic diseases;Theranostics;2023